All News
Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors
Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.
Read Article
More severe COVID-19 outcomes in African American, Hispanic individuals with SLE
A study from ACR21 convergence discussing data from the Global Rheumatology Alliance (GRA) describes the association between race/ethnicity on COVID-19 outcomes specifically in lupus patients.
Read Article
Health Disparities: Dr. Arthur Kavanaugh discussed how a number of studies presented at the #ACR21 annual meeting are looking at the impact of socioeconomic factors and race on outcomes.
https://t.co/KunXNfbaRk https://t.co/b8SgnXmrZO
Links:
Dr. John Cush RheumNow ( View Tweet)
Potpourri of Biosimilar Trials: Dr. Jonathan Kay discusses a number of biosimilar trials presented at the #ACR21 annual meeting, including abstracts #0822, #0820, #0817 and #0823.
https://t.co/aQXrKKZXhb https://t.co/4Bn7rvogHY
Links:
Dr. John Cush RheumNow ( View Tweet)
Updates on New Treatments for SpA: Drs. Antoni Chan ( @synovialjoints) interviews Dr. Laura Coates discuss a number of studies related to new treatments for SpA presented at the #ACR21 annual meeting.
https://t.co/mOutSekQkJ https://t.co/JG18q9PsdD
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of PSA from Sunday Sessions: Dr. Rachel Tate ( @uptoTate) discusses the RheumNow PSA faculty's best PsA abstracts from Sunday sessions, including abstracts #0750 and #0944, which were presented at the #ACR21 annual meeting.
https://t.co/wgMq2rsWNj https://t.co/Z2By90rBEy
Links:
Dr. John Cush RheumNow ( View Tweet)
Lipidomic Differences in PsA and RA: Dr. Pedro Castillo ( @_Castillo_Pedro) discusses abstract #0946 presented at the #ACR21 annual meeting.
https://t.co/M8O1OdvFAk https://t.co/4QMgXPhLzn
Links:
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Levels in Type I and 2 Lupus: Bella Mehta ( @bella_mehta) interviews Dr. Megan Clowse about abstract #0877, presented at the #ACR21 annual meeting.
https://t.co/L62iO8J9QF https://t.co/Oy58jbPPts
Links:
Dr. John Cush RheumNow ( View Tweet)
Treat to Target in SLE: Dr. Yuzaiful Yusof ( @Yuz6Yusof ) reviews abstract #0865 presented at the #ACR21 annual meeting.
https://t.co/THX4nLWCaR https://t.co/951HAdkONi
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Dr. Aurelie Nahm ( @AurelieRheumo) shares #ACR21 presentation findings on TNF inhibitors and radiographic progression in axSpA
https://t.co/nDh6sT1MzX https://t.co/5Ri13bfYOV
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: New Insights into Uveitis in Spondyloarthritis
There have been some updates on uveitis in SpA at #ACR21 shared by Dr. Antoni Chan ( @synovialjoints).
https://t.co/lyKt8p5s4o https://t.co/A9tRmD4mBJ https://t.co/TZPThjrazR
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: To Clot or Not to Clot with Drs. Janet Pope ( @Janetbirdope) and Jeffrey Sparks ( @jeffsparks )
#ACR21
https://t.co/HL6rGMqFRN https://t.co/YeWP4kKJhD https://t.co/7DyIXPPOLL
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Monitoring Infliximab Drug Levels Improves Efficacy
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
Dr. Robert Chao ( @doctorRBC) shares data presented at #ACR21.
https://t.co/zkxvUrsczd
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Watch: Lupus Updates: Dr. Michelle Petri
Dr. Michelle Petri offers perspective and insight into lupus related data presented Saturday at the #ACR21 annual meeting.
https://t.co/nluRreQPT1 https://t.co/fzm1RW6Rpy
Links:
Dr. John Cush RheumNow ( View Tweet)
In case you missed it…
Watch: What's Cool and Hot in Vasculitis with Dr. Janet Pope (@Janetbirdope ) #ACR21
https://t.co/JbhQWeejy7 https://t.co/qlCCk3MXKu
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS)
Dr. Sheila Reyes(@RHEUMarampa) discusses the three interesting abstracts were presented by the group of Prof. Marco Garrido-Cumbrera on the EMAS at #ACR21.
https://t.co/5kOv5BUU4P https://t.co/lKuXC0mLRt
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC )
#ACR21
https://t.co/jRLem8YWpv https://t.co/5EQB1Y38Xs
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: COVID in Rheumatologic Disease Patients: Drs. Sparks, Liew, Yazdany and Dao provide an update on data specific to COVID in rheumatologic disease patients.
@jeffsparks @drdavidliew @KDAO2011
#ACR21
https://t.co/jDGCpyTaPa https://t.co/58aehXyNzY
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Towards better assessment and management of multimorbidity by Dr. Mrinalini Dey ( @DrMiniDey ) #ACR21
https://t.co/5G7PkWYrOH https://t.co/olsfrCyJw5
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast - #ACR21 Rehash (the good stuff…)
The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
https://t.co/6tuiajP4O7 https://t.co/cZeeVmrHqR
Links:
Dr. John Cush RheumNow ( View Tweet)
